Detalles de la búsqueda
1.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36657420
2.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Liver Int
; 43(8): 1803-1812, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37452505
3.
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
Hepatol Res
; 52(12): 1050-1059, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35960789
4.
BRCA-mutant pancreatic ductal adenocarcinoma.
Br J Cancer
; 125(10): 1321-1332, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34262146
5.
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients
Future Oncol
; 16(2): 4337-4339, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31793396
6.
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.
Cancers (Basel)
; 16(7)2024 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611042
7.
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
Target Oncol
; 19(2): 223-235, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38345693
8.
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Target Oncol
; 2024 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38689194
9.
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?
Expert Rev Anticancer Ther
; 23(1): 19-27, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36472371
10.
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.
Expert Rev Clin Pharmacol
; 16(7): 631-642, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37387533
11.
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression.
Cancers (Basel)
; 15(4)2023 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36831554
12.
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Dig Liver Dis
; 55(5): 655-660, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36513569
13.
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
Ther Adv Med Oncol
; 15: 17588359231171574, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37457302
14.
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index.
Anticancer Res
; 43(4): 1599-1610, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36974779
15.
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors.
Sci Rep
; 13(1): 4397, 2023 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36928082
16.
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Target Oncol
; 18(1): 139-145, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689074
17.
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Front Oncol
; 13: 1177681, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441419
18.
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
J Cancer Res Clin Oncol
; 149(9): 5591-5602, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36509984
19.
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
J Cancer Res Clin Oncol
; 149(10): 7565-7577, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36976353
20.
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Target Oncol
; 18(2): 221-233, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36920648